نتائج البحث

1

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

المؤلفون: Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, Mark B Leick, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Nora Horick, Paul O'Donnell, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V Maus, Matthew J Frigault

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d85a6ea0ca4b61de8056237a10d497bTest
https://pubmed.ncbi.nlm.nih.gov/34996813Test

2

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)

مصطلحات موضوعية: Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Immunology, Programmed Cell Death 1 Receptor, Ipilimumab, Drug resistance, central nervous system neoplasms, Young Adult, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, melanoma, Immunology and Allergy, Humans, tumor microenvironment, Protein Kinase Inhibitors, RC254-282, Aged, Pharmacology, Trametinib, Mitogen-Activated Protein Kinase Kinases, Clinical/Translational Cancer Immunotherapy, business.industry, Brain Neoplasms, Melanoma, Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Dabrafenib, Gene signature, Middle Aged, medicine.disease, Nivolumab, Molecular Medicine, Female, immunotherapy, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da968995061b958d23940d09e9ea9125Test
https://pubmed.ncbi.nlm.nih.gov/34625515Test

3

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

المؤلفون: Christian Posch, Veronica Aedo-Lopez, Julian Kofler, Julia Maria Ressler, Peter Koelblinger, Matthias Karasek, Christoph Hoeller, Christine Hafner, Helmut Kehrer, Olivier Michielin, Rita Silmbrod, Felix Weihsengruber, Erika Richtig, Lukas Koch, Sofiya Latifyan, Joanna Mangana

المساهمون: University of Zurich, Ressler, Julia Maria

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for immunotherapy of cancer, vol. 9, no. 2, pp. e001701

مصطلحات موضوعية: 0301 basic medicine, medicine.medical_specialty, Cancer Research, Metastatic lesions, Immunology, 610 Medicine & health, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Immunology and Allergy, 1306 Cancer Research, Stage (cooking), Adverse effect, RC254-282, Pharmacology, 2403 Immunology, business.industry, Melanoma, 10177 Dermatology Clinic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Treatment period, ddc, Adult, Aged, Aged, 80 and over, Biological Products/adverse effects, Biological Products/therapeutic use, Disease Progression, Europe, Female, Herpesvirus 1, Human/immunology, Herpesvirus 1, Human/pathogenicity, Humans, Male, Melanoma/immunology, Melanoma/pathology, Melanoma/therapy, Middle Aged, Neoplasm Staging, Oncolytic Viruses/immunology, Oncolytic Viruses/pathogenicity, Retrospective Studies, Skin Neoplasms/immunology, Skin Neoplasms/pathology, Skin Neoplasms/therapy, Skin Neoplasms/virology, Time Factors, Treatment Outcome, immunotherapy, melanoma, oncolytic virotherapy, oncolytic viruses, 030104 developmental biology, 3004 Pharmacology, Oncology, 030220 oncology & carcinogenesis, 1313 Molecular Medicine, Cohort, 2723 Immunology and Allergy, Molecular Medicine, 2730 Oncology, business, Talimogene laherparepvec, Progressive disease

وصف الملف: application/pdf; Nr._14_Real-life_ust_of_talimogene_laherparepvec.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed27d867e0f6ae9e5fa254d7177dae2cTest
https://mediatum.ub.tum.de/1653382Test

4

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, medicine.medical_treatment, Herpesvirus 1, Human, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immunology and Allergy, Medicine, RC254-282, Tumor Biomarkers, Aged, 80 and over, Oncolytic Virotherapy, medicine.diagnostic_test, Soft tissue sarcoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Sarcoma, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Preoperative Period, Molecular Medicine, Female, Radiology, Talimogene laherparepvec, Adult, medicine.medical_specialty, Immunology, 03 medical and health sciences, Biopsy, Humans, Clinical Trials, Aged, Pharmacology, Myxoid liposarcoma, Biological Products, Radiotherapy, business.industry, Phase II as Topic, Extremities, medicine.disease, Oncolytic virus, Clinical trial, Radiation therapy, Oncolytic and Local Immunotherapy, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e946535cd1aa54618adf1d03683614Test
https://pubmed.ncbi.nlm.nih.gov/34330766Test

5

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Cutaneous squamous cell carcinoma, Skin Neoplasms, Immunology, Locally advanced, Medizin, Phases of clinical research, Antibodies, Monoclonal, Humanized, programmed cell death 1 receptor, Quality of life, Pain control, Internal medicine, Clinical endpoint, Immunology and Allergy, Medicine, Humans, RC254-282, Aged, Pharmacology, Aged, 80 and over, Clinical/Translational Cancer Immunotherapy, clinical trials, business.industry, phase II as topic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Clinical trial, Clinical research, Treatment Outcome, Oncology, Carcinoma, Squamous Cell, Quality of Life, Molecular Medicine, Female, immunotherapy, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9f2aac34ecf7e37b97af0c00e1a639Test
https://pubmed.ncbi.nlm.nih.gov/34413166Test

6

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for Immunotherapy of Cancer

مصطلحات موضوعية: Oncology, Adult, Cancer Research, medicine.medical_specialty, Durvalumab, medicine.medical_treatment, Immunology, Phases of clinical research, DNA Mismatch Repair, programmed cell death 1 receptor, Drug Administration Schedule, Antineoplastic Agents, Immunological, Internal medicine, Clinical endpoint, Immunology and Allergy, Medicine, Humans, Adverse effect, RC254-282, Aged, Pharmacology, Clinical/Translational Cancer Immunotherapy, Chemotherapy, clinical trials, business.industry, Endometrial cancer, phase II as topic, Antibodies, Monoclonal, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, medicine.disease, Survival Analysis, Endometrial Neoplasms, Clinical trial, Treatment Outcome, Cohort, Molecular Medicine, Female, immunotherapy, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a56b01ba8ce00e7efa33f5ce36561b0Test
https://jitc.bmj.com/content/9/6/e002255.fullTest

7

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III

المؤلفون: Peixin Chen, Chunyan Wu, Minlin Jiang, Yi Xu, Liping Zhang, Jun Zhu, Chenglong Sun, Yayi He, Jia Yu, Caicun Zhou, Shengyu Wu, Hao Wang, Qiyu Fang, Hui Sun, Wencheng Zhao, Zixuan Zheng

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer

مصطلحات موضوعية: lymphocytes, Male, Oncology, Cancer Research, Lung Neoplasms, Time Factors, Machine Learning, Risk Factors, Immunotherapy Biomarkers, Tumor Microenvironment, Immunology and Allergy, RC254-282, Aged, 80 and over, Framingham Risk Score, biology, FOXP3, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Forkhead Transcription Factors, Middle Aged, Immunohistochemistry, Treatment Outcome, Molecular Medicine, Female, Adult, tumor, medicine.medical_specialty, CD3, Immunology, chemical and pharmacologic phenomena, Risk Assessment, programmed cell death 1 receptor, Decision Support Techniques, Immune system, Predictive Value of Tests, Internal medicine, Biomarkers, Tumor, medicine, Humans, Lung cancer, Aged, Neoplasm Staging, Retrospective Studies, Pharmacology, Tumor microenvironment, business.industry, biomarkers, tumor-infiltrating, medicine.disease, Small Cell Lung Carcinoma, Nomograms, biology.protein, Neoplasm Recurrence, Local, business, CD8

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a0c7a5fab406d27ac6fcb367c98307Test
https://jitc.bmj.com/content/9/5/e002339.fullTest

8

Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

المؤلفون: Chunyan Lan, Zhimin Liu, Dongqin Zhu, Fan Yang, Minjun He, Hongyu Peng, Chongjie Tong, Xiao-Long Zhang, Xin Huang, Jiani C. Yin, Junli Zhang, Yang Shao

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Time Factors, Pyridines, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Phases of clinical research, Uterine Cervical Neoplasms, chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Immunotherapy Biomarkers, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Apatinib, Immune Checkpoint Inhibitors, RC254-282, Cervical cancer, biology, medicine.diagnostic_test, High-Throughput Nucleotide Sequencing, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Progression-Free Survival, drug therapy, Gene Expression Regulation, Neoplastic, 030220 oncology & carcinogenesis, Disease Progression, Molecular Medicine, Female, immunotherapy, Signal Transduction, Adult, medicine.medical_specialty, Combination therapy, Immunology, Antibodies, Monoclonal, Humanized, Risk Assessment, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, Biopsy, medicine, PTEN, Humans, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, Aged, combination, Pharmacology, business.industry, Gene Expression Profiling, Immunotherapy, medicine.disease, 030104 developmental biology, chemistry, genetic markers, biology.protein, business, Transcriptome

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04b4bdd5597fc08e7efbeb45dcf1695Test
https://jitc.bmj.com/content/9/5/e002223.fullTest

9

Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood

المؤلفون: Soudabeh Rad Pour, Xavier Martinez Demorentin, Yago Pico de Coaña, David Gomez-Cabrero, Maria Wolodarski, Johan Hansson, Manjula Thimma, Rolf Kiessling, Jeroen Melief, Jesper Tegnér

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Programmed Cell Death 1 Receptor, active, Monocytes, 0302 clinical medicine, Immunology and Allergy, RNA-Seq, Immune Checkpoint Inhibitors, Melanoma, RC254-282, Aged, 80 and over, Clinical/Translational Cancer Immunotherapy, medicine.diagnostic_test, CD4-CD8 ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Flow Cytometry, Nivolumab, Treatment Outcome, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Single-Cell Analysis, Adult, medicine.medical_specialty, Immunology, therapies, investigational, Peripheral blood mononuclear cell, Flow cytometry, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, gene expression profiling, medicine, Calgranulin B, Humans, Aged, Sweden, Pharmacology, business.industry, Monocyte, Immunotherapy, medicine.disease, Blockade, 030104 developmental biology, business, Checkpoint Blockade Immunotherapy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dce267ed6b6145ca7733d8384ece8faTest
https://jitc.bmj.com/content/9/5/e002171.fullTest

10

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck

المؤلفون: Angen Liu, Robert L. Ferris, Dan P. Zandberg, Ashley V. Menk, Maria A. Velez, Greg M. Delgoffe, Kristin DePeaux, Daniel P. Normolle

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)

مصطلحات موضوعية: 0301 basic medicine, lymphocytes, Male, Cancer Research, medicine.medical_treatment, T-Lymphocytes, Programmed Cell Death 1 Receptor, 0302 clinical medicine, Antineoplastic Agents, Immunological, Tumor Microenvironment, Immunology and Allergy, Immune Checkpoint Inhibitors, RC254-282, Clinical/Translational Cancer Immunotherapy, Aged, 80 and over, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunosuppression, Middle Aged, Progression-Free Survival, Tumor Burden, Oncology, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, medicine.symptom, metabolic networks and pathways, Oxidation-Reduction, Signal Transduction, Adult, Immunology, 03 medical and health sciences, head and neck neoplasms, Lymphocytes, Tumor-Infiltrating, Cell Line, Tumor, medicine, Pimonidazole, Animals, Humans, Progression-free survival, Aged, Retrospective Studies, Pharmacology, Tumor microenvironment, Tumor hypoxia, business.industry, Squamous Cell Carcinoma of Head and Neck, Immunotherapy, Hypoxia (medical), tumor-infiltrating, Xenograft Model Antitumor Assays, Mice, Inbred C57BL, 030104 developmental biology, Drug Resistance, Neoplasm, Cancer research, Tumor Hypoxia, business, Energy Metabolism, CD8

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a738a335f0dbb51e76431215797d38Test
http://europepmc.org/articles/PMC8126285Test

تنقيح النتائج